araag2/HINT huggingface dataset:
Clinical trial NCT00607373 (phase 3, status: completed)
Conditions: lipid metabolism, inborn errors, hypercholesterolemia, autosomal dominant, hyperlipidemias, metabolic diseases, hyperlipoproteinemia type ii, metabolism, inborn errors, genetic diseases, inborn, infant, newborn, diseases, metabolic disorder, congenital abnormalities, hypercholesterolemia, hyperlipoproteinemias, dyslipidemias, lipid metabolism disorders
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E78.01, E78.00, Z83.42, Z86.39, O99.280, O99.281, O99.282, O99.283, O99.284, O99.285, E71.42, P09.1, E88.9, O03.33, O04.83, O03.83, O07.33, E88.89, E89.89, Z36.83, Z82.79, E78.01, E78.00, Z83.42, Z83.438
Drugs: mipomersen, placebo
SMILES: [H]C1(CC([H])(OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C3NC(=N)N=C4O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C(N)N=CN=C34)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=NC3=C2NC(=N)N=C3O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)C([H])(COP(O)(=S)OC2([H])CC([H])(OC2([H])COP(O)(=S)OC2([H])C([H])(COP(O)(=S)OC3([H])C([H])(COP(O)(=S)OC4([H])C([H])(COP(O)(=S)OC5([H])C([H])(COP(O)(=S)OC6([H])C([H])(CO)OC([H])(N7C=NC8=C7NC(=N)N=C8O)C6([H])OCCOC)OC([H])(N6C=C(C)C(=N)N=C6O)C5([H])OCCOC)OC([H])(N5C=C(C)C(=N)N=C5O)C4([H])OCCOC)OC([H])(N4C=C(C)C(O)=NC4=O)C3([H])OCCOC)OC([H])(N3C=C(C)C(=N)N=C3O)C2([H])OCCOC)N2C=NC3=C(N)N=CN=C23)O1)N1C=NC2=C1NC(=N)N=C2O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH)

          -  Stable lipid-lowering therapy for 12 weeks

          -  Stable weight for 6 weeks

          -  Stable low fat diet for 8 weeks

        Exclusion Criteria:

          -  Significant health problems in the recent past including heart attack, stroke, blood
             disorders, cancer, or digestive problems
Clinical trial NCT00314977 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: doxorubicin, cyclophosphamide, docetaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Women presenting with large resectable or locally advanced breast cancer (T2 ≥3 cm,
             T3, or T4, and/or LN positive)

          -  Measurable disease (breast and/or lymph nodes)

          -  No prior surgery other than biopsy and no prior chemotherapy or radiation therapy

          -  Age ≥18 years and age ≤70 years

          -  Karnofsky Performance score ≥70%

          -  Estrogen and/or progesterone receptor analysis performed on the primary tumour in the
             biopsy material

          -  In case the tumor is ER/PgR ³ 50% positive, (neo)adjuvant hormonal therapy in stead of
             chemotherapy should be considered (e.g. in TEAM II study)

          -  Her2/neu receptor analysis performed on the primary tumour in the biopsy material

          -  Adequate bone marrow function (within 14 days prior to registration): WBC ≥3.0 x
             109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l

          -  Adequate liver function (within 4 weeks prior to start treatment): bilirubin ≤1.5 x
             upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase
             ≤5 x UNL

          -  Adequate renal function (within 4 weeks prior to start treatment): the calculated
             creatinine clearance should be ≥50 mL/min

          -  Patients must be accessible for treatment and follow-up

          -  Written informed consent according to the local Ethics Committee requirements

        Exclusion Criteria:

          -  Patients with advanced pulmonary disease of any cause (oxygen dependent)- Peripheral
             neuropathy > grade 2 whatever the cause

          -  Serious other diseases as recent myocardial infarction, clinical signs of cardiac
             failure or clinically significant arrythmias

          -  Evidence of distant metastases (M1)

          -  Patients with a history of breast cancer

          -  Patients with a history of another malignancy (except basal cell skin carcinoma and
             carcinoma-in-situ of the uterine cervix) within 5 years of study entry- Pregnant or
             lactating women, or potentially fertile women not using adequate contraception
Clinical trial NCT00206141 (phase 3, status: completed)
Conditions: bipolar disorder, bipolar depression, depression
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32, F32.A, F53.0, P91.4, Z13.31, Z13.32, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: quetiapine fumarate (seroquel™) drug, mood stabilizer (mood)
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of bipolar I disorder or bipolar II disorder, currently
             depressed, aged 18 to 65 years old and outpatient status at enrolment and
             randomization.

        Exclusion Criteria:

          -  Patients with a current DSM-IV Axis I disorder other than bipolar disorder that is
             symptomatic or requiring treatment within 6 months of enrolment,

          -  History of non-response to an adequate treatment

          -  Patients who, in the investigator's judgment pose a current serious suicidal or
             homicidal risk

          -  Pregnancy or lactation

          -  Clinically relevant disease or clinical finding
Clinical trial NCT00474786 (phase 3, status: completed)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib, temsirolimus (torisel)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy
             status) with well-documented Radiological PD by RECIST criteria or clinical PD as
             judged by the investigator while receiving first-line sunitinib therapy. Subjects must
             have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).

          -  At time of randomization, at least 2 weeks since prior treatment with sunitinib,
             palliative radiation therapy, and/or surgery.

          -  At time of randomization, there must be at least 1 measurable lesion per RECIST.
             Lesions that have been previously irradiated or embolized cannot be selected as target
             lesions.

               -  More criteria apply

        Exclusion Criteria:

          -  Metastatic CNS from RCC.

          -  Subjects who discontinued Sutent therapy due specifically to intolerance.

          -  Prior systemic therapy for mRCC other than sunitinib.

          -  Active ketonuria, secondary to poorly controlled diabetes mellitus

               -  More criteria apply
Clinical trial NCT01143090 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: lurasidone hcl
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has completed 6 weeks of treatment and all required assessments on the final
             study visit (Visit 8) of Study D1050289 (NCT01143077).

        Exclusion Criteria:

          -  Subject is considered by the investigator to be at imminent risk of suicide or harm to
             self, others, or damage to property.

          -  Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see
             Appendix 3 for BMI determination).
Clinical trial NCT00035048 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: aprepitant, comparator: placebo (unspecified)
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Patients with Major Depressive Disorder
Clinical trial NCT00443690 (phase 3, status: completed)
Conditions: heart failure, congestive
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: rolofylline, comparator: placebo (unspecified)
SMILES: CCCN1C2=C(NC(=N2)C23C[C@@H]4CC2C[C@H](C3)C4)C(=O)N(CCC)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Dyspnea at rest or with minimal exertion at randomization

          -  Fluid overload

          -  Estimated creatinine clearance (CrCl) between 20-60 mL/min

          -  Worsening renal function

          -  Anticipated need for IV diuretic treatment for at least 48 hours after the start of
             study drug

          -  BNP >500 pg/mL or NT-pro-BNP >2000 pg/mL

          -  Systolic blood pressure ≥90 mmHg at randomization

        Exclusion Criteria:

          -  IV radiographic contrast within 14 days

          -  IV vasodilators within 6 hours

          -  Serum potassium <3.5 meq/L

          -  Ongoing or planned therapy for heart failure with mechanical circulatory or
             ventilatory support

          -  Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis

          -  Rapidly progressive acute renal failure

          -  Evidence of acute tubular necrosis or post-obstructive nephropathy or other exogenous
             causes of acute kidney injury, unrelated to heart failure

          -  Severe pulmonary disease

          -  Significant stenotic mitral or aortic valvular disease

          -  Heart transplant recipient or admitted for cardiac transplantation or LVAD surgery

          -  Any major surgery within 2 weeks prior

          -  evidence of acute coronary syndrome in the 2 weeks prior

          -  Hgb <8 g/dL, Hct <25%, or active bleeding requiring transfusion

          -  Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive
             cardiomyopathy.

          -  Known hepatic impairment

          -  Non-cardiac pulmonary edema

          -  Temperature >38°C

          -  Sepsis or active infection requiring IV anti-microbial treatment

          -  Administration of an investigational drug or device within 30 days

          -  Current or anticipated therapy with atazanavir, clarithromycin, indinavir,
             itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,
             telithromycin, or voriconazole

          -  Administration of any vasopressor or inotropic drug within 72 hours

          -  History of seizure (except febrile seizure)

          -  Stroke within 2 years

          -  History of brain tumor of any etiology

          -  Brain surgery within 2 years

          -  Encephalitis/meningitis within 2 years

          -  History of penetrating head trauma

          -  Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years

          -  History of or at risk for alcohol withdrawal seizures

          -  Advanced Alzheimer's disease

          -  Advanced multiple sclerosis
Clinical trial NCT01229813 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, erlotinib, bevacizumab, bevacizumab, low dose capecitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Untreated metastatic colorectal carcinoma

          -  Age 18 yrs or over

          -  Measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST
             criteria)

          -  ECOG performance status 0 or 1

          -  Life expectancy more than 3 months

          -  Adequate haematological, renal and liver function

          -  Tumor tissue available for determination of KRAS mutational status

          -  Blood sample and paraffin embedded tumor tissue for translational research

        Exclusion Criteria:

          -  Adjuvant therapy within 6 months

          -  CNS metastases

          -  Clinically significant atherosclerotic vascular disease
Clinical trial NCT00729183 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: odanacatib, placebo, vitamin d3, calcium supplement
SMILES: CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, [Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has been postmenopausal for 3 years

          -  Participant has BMD t-score at the total hip, hip trochanter, femoral neck, or lumbar
             spine ≥ -1.5 but > -3.5

          -  Participant has 2 hips that are evaluable by dual-energy X-ray absorptiometry (DXA)
             and quantitative computed tomography (QCT), e.g. contain no hardware from orthopedic
             procedures

          -  Participant is ambulatory

        Exclusion Criteria:

          -  Participant has had a previous hip fracture

          -  Participant has had >1 prior clinical vertebral fracture AND is a candidate for
             osteoporosis therapy

          -  Participant has been treated with oral bisphosphonates, strontium, parathyroid hormone
             (PTH) or other agents with an effect on bone

          -  Participant has had metabolic bone disorder other than osteoporosis

          -  Participant has renal stones, Parkinson's disease, multiple sclerosis (MS) or active
             parathyroid disease.
Clinical trial NCT00097825 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male, 25-85 years old

        Exclusion Criteria:

          -  Current users of bisphosphonates such as Aredia® (pamidronate), Didronel®
             (etidronate), Fosamax® (alendronate), Actonel ® (residronate), Skelid® (tiludronate)

          -  History of severe liver, kidney or eye disease

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00260156 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Not currently on drug therapy for type 2 diabetes

          -  Blood glucose criteria must be met

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  Evidence of significant diabetic complications

          -  Serious cardiovascular events within the past 6 months

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT01026194 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo / teneli (teneligliptin) + pio (pioglitazone), teneli / teneli + pio
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who are 20 - 75 years old

          -  Patients who are under dietary management and taking therapeutic exercise for diabetes
             over 12 weeks before administration of investigational drug

          -  Patients whose HbA1c is between 6.5% and 10.0%

          -  Patients who took Thiazolidinedione for diabetes over 16 weeks before administration
             of investigational drug

          -  Patients who were not administered diabetes therapeutic drugs prohibited for
             concomitant use within 12 weeks before administration of investigational drug.

        Exclusion Criteria:

          -  Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or
             secondary diabetes (Cushing disease, acromegaly, etc)

          -  Patients who are accepting treatments of arrhythmias

          -  Patients with serious diabetic complications

          -  Patients who are the excessive alcohol addicts

          -  Patients with severe hepatic disorder or severe renal disorder.

          -  Patients who are pregnant, lactating, and probably pregnant patients, and patients who
             can not agree to contraception
Clinical trial NCT00142298 (phase 3, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: telbivudine (ldt)
SMILES: CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient completed a previous qualifying Idenix-Sponsored trial with telbivudine

          -  Patient was not discontinued from previous Idenix-Sponsored study

        Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Patient is pregnant or breastfeeding

          -  Patient is co-infected with hepatitis C, hepatitis D or HIV

        Other protocol-defined exclusion criteria may apply
Clinical trial NCT00283946 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders, sleep disorders
ICD codes: Y93.E9, Y93.H9, G47.9, G47.21, G47.22, G47.23, G47.52, G47.29, G47.20
Drugs: zolpidem mr, zolpidem
SMILES: CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of nonorganic insomnia.

          -  Must be able to swallow tablets

        Exclusion Criteria:

          -  Allergic reactions to zolpidem (Myslee)

          -  Serious cardiac disorders; Serious hepatic impairment; Serious renal diseases, etc.
Clinical trial NCT00567164 (phase 3, status: completed)
Conditions: contraception, ovulation inhibition, contraceptives, oral
ICD codes: Z92.0, Z30.012, Z30.09, N92.3, T38.4X6S, T38.4X3S, T38.4X4S, T38.4X5S, T38.4X6A, T38.4X6D, T38.4X1S
Drugs: ee20/drsp (bay86-5300), ee20/drsp (bay86-5300), ee20/drsp (yaz, bay86-5300)
SMILES: [H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21, [H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

        - Healthy women between 18 and 45 requesting oral contraception. Smokers may not exceed 35
        years of age.

        Exclusion Criteria:

        - The use of steroidal oral contraceptives, or any drug that could alter oral contraception
        metabolism will be prohibited during the study.
Clinical trial NCT01468181 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, sulfonylureas (su), biguanides (bg), alpha-glucosidase inhibitor (a-gi), thiazolidinedione (tzd), glinides
SMILES: COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O, CN(C)C(=N)NC(N)=N, O=C1CSC(=O)N1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who have had a diagnosis of type 2 diabetes mellitus before screening

          -  Participants who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), BG,
             TZD, a-GI or glinides monotherapy for at least 3 months before screening and have been
             on a stable dose for at least 8 weeks before screening

          -  Participants must have a qualifying HbA1c value of 7.0% to 11.0% at screening

          -  Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter
             squared (kg/m^2)

        Exclusion Criteria:

          -  Participants who have a diagnosis of type 1 diabetes

          -  Participants who have previously been treated with any other glucagon-like peptide-1
             (GLP-1) analog within the 3 months before screening

          -  Participants who are currently taking insulin or have had previous insulin treatment
             within the 3 months before screening

          -  Participants who have obvious clinical signs or symptoms of pancreatitis, a history of
             chronic pancreatitis, or acute pancreatitis at screening, as determined by the
             investigator. Participants who have a serum amylase concentration ≥3 times the upper
             limit of the reference range and/or a serum lipase concentration ≥2 times the upper
             limit of the reference range, as determined by the central laboratory at screening

          -  Participants who have self or family history of medullary C-cell hyperplasia, focal
             hyperplasia, or medullary thyroid carcinoma (MTC)